Companies Dominating the Meloxicam Landscape
- Taj Pharmaceutical Limited.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Wellona Pharma
- Trumac Healthcare
- Healthy Life Pharma Private Limited.
- EPICON LIFESCIENCES LLP
- Boehringer Ingelheim GmbH.
- Baudax Bio
- Heron Therapeutics Inc.
- Avanstra Inc.
- PD-Rx Pharmaceuticals, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of meloxicam is estimated at USD 7.64 billion.
The meloxicam market size was valued at USD 7.34 billion in 2024 and is likely to cross USD 13.5 billion by 2037, registering more than 4.8% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of chronic pain disease and increasing research and development in meloxicam will boost the market growth.
North America industry is set to account for largest revenue share of 33% by 2037, impelled by growing prevalence of arthritis in the region.
The major players in the market are Healthy Life Pharma Private Limited., EPICON LIFESCIENCES LLP, Boehringer Ingelheim GmbH., Baudax Bio, Heron Therapeutics Inc., Avanstra Inc., PD-Rx Pharmaceuticals, Inc., and others.
